Although fluoride increases bone mass, the newly formed bone may have reduced strength. To assess the effect of fluoride treatment on the fracture rate in osteoporosis, we conducted a four-year prospective clinical trial in 202 postmenopausal women with osteoporosis and vertebral fractures who were randomly assigned to receive sodium fluoride (75 mg per day) or placebo. All received a calcium supplement (1500 mg per day). Sixty-six women in the fluoride group and 69 women in the placebo group completed the trial. As compared with the placebo group, the treatment group had increases in median bone mineral density of 35 percent (P less than 0.0001) in the lumbar spine (predominantly cancellous bone), 12 percent (P less than 0.0001) in the femoral neck, and 10 percent (P less than 0.0001) in the femoral trochanter (sites of mixed cortical and cancellous bone), but the bone mineral density decreased by 4 percent (P less than 0.02) in the shaft of the radius (predominantly cortical bone). The number of new vertebral fractures was similar in the treatment and placebo groups (163 and 136, respectively; P not significant), but the number of nonvertebral fractures was higher in the treatment group (72 vs. 24; P less than 0.01). Fifty-four women in the fluoride group and 24 in the placebo group had side effects sufficiently severe to warrant dose reduction; the major side effects were gastrointestinal symptoms and lower-extremity pain. We conclude that fluoride therapy increases cancellous but decreases cortical bone mineral density and increases skeletal fragility. Thus, under the conditions of this study, the fluoride-calcium regimen was not effective treatment for postmenopausal osteoporosis.
Source Information
Division of Endocrinology, Metabolism, and Internal Medicine, Mayo Clinic, Rochester, Minn. 55905.
This article has been cited by other articles:
LICATA, A.
(2009). Bone density vs bone quality: What's a clinician to do?. Cleveland Clinic Journal of Medicine
76: 331-336
[Abstract][Full Text]
Hunt, J. R., Hunt, C. D., Zito, C. A., Idso, J. P., Johnson, L. K.
(2008). Calcium Requirements of Growing Rats Based on Bone Mass, Structure, or Biomechanical Strength Are Similar. J. Nutr.
138: 1462-1468
[Abstract][Full Text]
MacLaughlin, E. J., Raehl, C. L.
(2008). ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults. Am J Health Syst Pharm
65: 343-357
[Full Text]
Reid, I. R., Cundy, T., Grey, A. B., Horne, A., Clearwater, J., Ames, R., Orr-Walker, B. J., Wu, F., Evans, M. C., Gamble, G. D., King, A.
(2007). Addition of Monofluorophosphate to Estrogen Therapy in Postmenopausal Osteoporosis: A Randomized Controlled Trial. J. Clin. Endocrinol. Metab.
92: 2446-2452
[Abstract][Full Text]
Johnson, J. E. H., Kearns, A. E., Doran, P. M., Khoo, T. K., Wermers, R. A.
(2007). Fluoride-Related Bone Disease Associated With Habitual Tea Consumption. Mayo Clin Proc.
82: 719-724
[Abstract][Full Text]
Cunningham, J.
(2007). Pathogenesis and Prevention of Bone Loss in Patients Who Have Kidney Disease and Receive Long-Term Immunosuppression. J. Am. Soc. Nephrol.
18: 223-234
[Abstract][Full Text]
Weber, W. A., Figlin, R.
(2007). Monitoring Cancer Treatment with PET/CT: Does It Make a Difference?. JNM
48: 36S-44S
[Abstract][Full Text]
Bouletreau, P. H, Bost, M., Fontanges, E., Lauverjat, M., Gutknecht, C., Ecochard, R., Delmas, P. D, Chambrier, C.
(2006). Fluoride exposure and bone status in patients with chronic intestinal failure who are receiving home parenteral nutrition. Am. J. Clin. Nutr.
83: 1429-1437
[Abstract][Full Text]
Gill, S., Sargent, D.
(2006). End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival?. The Oncologist
11: 624-629
[Abstract][Full Text]
Sowers, M., Whitford, G. M., Clark, M. K., Jannausch, M. L.
(2005). Elevated Serum Fluoride Concentrations in Women Are Not Related to Fractures and Bone Mineral Density. J. Nutr.
135: 2247-2252
[Abstract][Full Text]
Rosen, C. J.
(2005). Postmenopausal Osteoporosis. NEJM
353: 595-603
[Full Text]
Fogelman, I., Blake, G. M
(2005). Strontium ranelate for the treatment of osteoporosis. BMJ
330: 1400-1401
[Full Text]
Biesbrock, A.R., Chesters, R.K., Ellwood, R.P., Smith, S.R.
(2004). The Challenges of Validating Diagnostic Methods Relative to a Conventional Two-year Caries Clinical Trial. JDR
83: C53-C55
[Abstract][Full Text]
(2004). Grading quality of evidence and strength of recommendations. BMJ
328: 1490-
[Abstract][Full Text]
Hodsman, A. B., Hanley, D. A., Ettinger, M. P., Bolognese, M. A., Fox, J., Metcalfe, A. J., Lindsay, R.
(2003). Efficacy and Safety of Human Parathyroid Hormone-(1-84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis. J. Clin. Endocrinol. Metab.
88: 5212-5220
[Abstract][Full Text]
Brown, J. P., Josse, R. G.
(2003). Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada. CMAJ
168: SF1-38
[Abstract][Full Text]
Brown, J. P., Josse, R. G.
(2002). 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ
167: s1-34
[Abstract][Full Text]
Crandall, C.
(2002). Parathyroid Hormone for Treatment of Osteoporosis. Arch Intern Med
162: 2297-2309
[Abstract][Full Text]
Peacock, M., Turner, C. H., Econs, M. J., Foroud, T.
(2002). Genetics of Osteoporosis. Endocr. Rev.
23: 303-326
[Abstract][Full Text]
Rothwell, P. M.
(2002). Why Do Clinicians Sometimes Find it Difficult to Use the Results of Systematic Reviews in Routine Clinical Practice?. Eval Health Prof
25: 200-209
[Abstract]
Wu, C.-H., Yang, Y.-C., Yao, W.-J., Lu, F.-H., Wu, J.-S., Chang, C.-J.
(2002). Epidemiological Evidence of Increased Bone Mineral Density in Habitual Tea Drinkers. Arch Intern Med
162: 1001-1006
[Abstract][Full Text]
Holloway, R. G., Dick, A. W.
(2002). Clinical trial end points: On the road to nowhere?. Neurology
58: 679-686
[Abstract][Full Text]
Reeve, J.
(2002). Recombinant human parathyroid hormone. BMJ
324: 435-436
[Full Text]
Rubin, C. D., Pak, C. Y. C., Adams-Huet, B., Genant, H. K., Li, J., Rao, D. S.
(2001). Sustained-Release Sodium Fluoride in the Treatment of the Elderly With Established Osteoporosis. Arch Intern Med
161: 2325-2333
[Abstract][Full Text]
Jones, G., Connett, P., Gibson, S. L M, Gibson, R. G, Holloway, P J, McDonagh, M. S, Kleijnen, J., Schmidt, T C, Phipps, K., Orwoll, E., Mason, J., Cauley, J., Baldwin, E., Mac Auley, D.
(2001). Water fluoridation. BMJ
322: 1486-1486
[Full Text]
Recker, R. R., Heaney, R. P.
(2001). The Role of Combination Treatment for Osteoporosis. J. Clin. Endocrinol. Metab.
86: 1888-1889
[Full Text]
Rosen, C. J., Bilezikian, J. P.
(2001). Anabolic Therapy for Osteoporosis. J. Clin. Endocrinol. Metab.
86: 957-964
[Abstract][Full Text]
Rodan, G. A., Martin, T. J.
(2000). Therapeutic Approaches to Bone Diseases. Science
289: 1508-1514
[Abstract][Full Text]
Cummings, S. R., Bauer, D. C.
(2000). Do Statins Prevent Both Cardiovascular Disease and Fracture?. JAMA
283: 3255-3257
[Full Text]
Horwitz, M., Stewart, A., Greenspan, S. L.
(2000). Editorial: Sequential Parathyroid Hormone/Alendronate Therapy for Osteoporosis--Robbing Peter to Pay Paul?. J. Clin. Endocrinol. Metab.
85: 2127-2128
[Full Text]
Ilich, J. Z., Kerstetter, J. E.
(2000). Nutrition in Bone Health Revisited: A Story Beyond Calcium. J. Am. Coll. Nutr.
19: 715-737
[Abstract][Full Text]
ROTHWELL, P M
(2000). Responsiveness of outcome measures in randomised controlled trials in neurology. J. Neurol. Neurosurg. Psychiatry
68: 274-275
[Full Text]
Wasnich, R. D., Miller, P. D.
(2000). Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone Density. J. Clin. Endocrinol. Metab.
85: 231-236
[Abstract][Full Text]
Alexandersen, P., Riis, B. J., Christiansen, C.
(1999). Monofluorophosphate Combined with Hormone Replacement Therapy Induces a Synergistic Effect on Bone Mass by Dissociating Bone Formation and Resorption in Postmenopausal Women: A Randomized Study. J. Clin. Endocrinol. Metab.
84: 3013-3020
[Abstract][Full Text]
Bucher, H. C., Guyatt, G. H., Cook, D. J., Holbrook, A., McAlister, F. A., for the Evidence-Based Medicine Working Group,
(1999). Users' Guides to the Medical Literature: XIX. Applying Clinical Trial Results; A. How to Use an Article Measuring the Effect of an Intervention on Surrogate End Points. JAMA
282: 771-778
[Full Text]
Suarez, F. L, Adshead, J., Furne, J. K, Levitt, M. D
(1999). Reply to WB Grant. Am. J. Clin. Nutr.
70: 302-303
[Full Text]
Hersh, A. L, Black, W. C, Tosteson, A. N.
(1999). Estimating the population impact of an intervention: a decision-analytic approach. Stat Methods Med Res
8: 311-330
[Abstract]
Recker, R. R., Davies, K. M., Dowd, R. M., Heaney, R. P.
(1999). The Effect of Low-Dose Continuous Estrogen and Progesterone Therapy with Calcium and Vitamin D on Bone in Elderly Women: A Randomized, Controlled Trial. ANN INTERN MED
130: 897-904
[Abstract][Full Text]
Greenspan, S. L.
(1999). A 73-Year-Old Woman With Osteoporosis. JAMA
281: 1531-1540
[Full Text]
Weil, V. P.
(1999). Fluoride for the Treatment of Osteoporosis. ANN INTERN MED
130: 240-240
[Full Text]
Hartke, J. R.
(1999). Preclinical Development of Agents for the Treatment of Osteoporosis. Toxicol Pathol
27: 143-147
[Abstract]
Phipps, K.R., Orwoll, E.S., Bevan, L.
(1998). The Association Between Water-borne Fluoride and Bone Mineral Density in Older Adults. JDR
77: 1739-1748
[Abstract]
Eastell, R.
(1998). Treatment of Postmenopausal Osteoporosis. NEJM
338: 736-746
[Full Text]
Roland, M., Torgerson, D. J
(1998). Understanding controlled trials: What are pragmatic trials?. BMJ
316: 285-285
[Full Text]
Lems, W. F, Jacobs, J. W G, Bijlsma, J. W J, van Veen, G. J M, Houben, H. H M L, Haanen, H. C M, Gerrits, M. I, van Rijn, H. J M
(1997). Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?. Ann Rheum Dis
56: 357-363
[Abstract][Full Text]
Karpf, D. B., Shapiro, D. R., Seeman, E., Ensrud, K. E., Johnston, C. C. Jr, Adami, S., Harris, S. T., Santora, A. C. II, Hirsch, L. J., Oppenheimer, L., Thompson, D.
(1997). Prevention of Nonvertebral Fractures by Alendronate: A Meta-analysis. JAMA
277: 1159-1164
[Abstract]
Holloway, L., Kohlmeier, L., Kent, K., Marcus, R.
(1997). Skeletal Effects of Cyclic Recombinant Human Growth Hormone and Salmon Calcitonin in Osteopenic Postmenopausal Women. J. Clin. Endocrinol. Metab.
82: 1111-1117
[Abstract][Full Text]
Hodsman, A. B., Fraher, L. J., Watson, P. H., Ostbye, T., Stitt, L. W., Adachi, J. D., Taves, D. H., Drost, D.
(1997). A Randomized Controlled Trial to Compare the Efficacy of Cyclical Parathyroid Hormone Versus Cyclical Parathyroid Hormone and Sequential Calcitonin to Improve Bone Mass in Postmenopausal Women with Osteoporosis. J. Clin. Endocrinol. Metab.
82: 620-628
[Abstract][Full Text]
Watts, N. B., Blevins, L. S. Jr
(1996). Endocrinology. JAMA
275: 1806-1807
[Abstract]
LANE, J. M., RILEY, E. H., WIRGANOWICZ, P. Z.
(1996). Instructional Course Lectures, The American Academy of Orthopaedic Surgeons - Osteoporosis: Diagnosis and Treatment*{{dagger}}. JBJS
78: 618-32
[Full Text]
Liberman, U. A., Weiss, S. R., Broll, J., Minne, H. W., Quan, H., Bell, N. H., Rodriguez-Portales, J., Downs, R. W., Dequeker, J., Favus, M., Seeman, E., Recker, R. R., Capizzi, T., Santora, A. C., Lombardi, A., Shah, R. V., Hirsch, L. J., Karpf, D. B., The Alendronate Phase III Osteoporosis Treatment S,
(1995). Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis. NEJM
333: 1437-1444
[Abstract][Full Text]
Bergmann, K.E., Bergmann, R.L.
(1995). Salt Fluoridation and General Health. ADR
9: 138-143
[Abstract]
Windeler, J., Lange, S.
(1995). Events per person year--a dubious concept. BMJ
310: 454-456
[Full Text]
Kleerekoper, M.
(1994). Non-Dental Tissue Effects of Fluoride. ADR
8: 32-38
[Abstract]
Ott, S M
(1994). Bone mass measurements: reasons to be cautious. BMJ
308: 931-932
[Full Text]
Sambrook, P., Birmingham, J., Kelly, P., Kempler, S., Nguyen, T., Pocock, N., Eisman, J.
(1993). Prevention of Corticosteroid Osteoporosis -- A Comparison of Calcium, Calcitriol, and Calcitonin. NEJM
328: 1747-1752
[Abstract][Full Text]
(1993). Knowledge of the Purpose of Community Water Fluoridation--United States, 1990. JAMA
269: 29-32
Danielson, C., Lyon, J. L., Egger, M., Goodenough, G. K.
(1992). Hip Fractures and Fluoridation in Utah's Elderly Population. JAMA
268: 746-748
[Abstract]
Koo, W. W.K.
(1992). Review: Parenteral Nutrition-Related Bone Disease. JPEN J Parenter Enteral Nutr
16: 386-394
[Abstract]
Lufkin, E. G., Wahner, H. W., O'Fallon, W. M., Hodgson, S. F., Kotowicz, M. A., Lane, A. W., Judd, H. L., Caplan, R. H., Riggs, B. L.
(1992). Treatment of Postmenopausal Osteoporosis with Transdermal Estrogen. ANN INTERN MED
117: 1-9
[Abstract]
Ott, S. M.
(1992). Estrogen Therapy for Osteoporosis--Even in the Elderly. ANN INTERN MED
117: 85-86
[Abstract]
(1991). Public Health Service Report on Fluoride Benefits and Risks. JAMA
266: 1061-1067
Cooper, C., Wickham, C. A. C., Barker, D. J. R., Jacobsen, S. J.
(1991). Water Fluoridation and Hip Fracture. JAMA
266: 513-514
[Abstract]
Ray, W. A.
(1991). Thiazide Diuretics and Osteoporosis: Time for a Clinical Trial?. ANN INTERN MED
115: 64-65
[Abstract]
Stoeckle, J. D., Goodson, J. D.
(1991). General Internal Medicine. JAMA
265: 3123-3125
[Abstract]
Larson, E. B.
(1991). Geriatric Medicine. JAMA
265: 3125-3126
[Abstract]
(1990). FLUORIDE NOT HELPFUL, AND POSSIBLY HARMFUL, IN OSTEOPOROSIS. JWatch General
1990: 3-3
[Full Text]
Previous
